

Supplementary Table 1. Demographic, socioeconomic and clinical data of patients

	Total (n = 215)	RA (n = 114)	SLE (n = 101)
Age at symptom onset (yr)	41.9 ± 14.4	48.9 ± 12.0	34.0 ± 12.8
Age at diagnosis (yr)	43.7 ± 14.6	51.0 ± 11.9	35.4 ± 12.8
Smoking			
Current	30 (14.0)	19 (16.7)	11 (10.9)
Quit	4 (1.9)	4 (3.5)	0 (0.0)
Alcohol			
Soju	52 (24.2)	28 (24.6)	24 (23.8)
Beer	5 (2.3)	4 (3.5)	1 (1.0)
Married status			
Single	30 (14.0)	6 (5.3)	24 (23.8)
Married	160 (74.4)	94 (82.5)	66 (65.3)
Bereaved	10 (4.7)	7 (6.1)	3 (3.0)
Divorced	14 (6.5)	6 (5.3)	8 (7.9)
Occupation			
Student	2 (0.9)	1 (0.9)	1 (1.0)
Housewife	100 (46.5)	55 (48.2)	45 (44.6)
Office worker	20 (9.3)	8 (7.0)	12 (11.9)
Profession	8 (3.7)	4 (3.5)	4 (4.0)
Self-employed	17 (7.9)	12 (10.5)	5 (5.0)
Education/public worker	2 (0.9)	0 (0.0)	2 (2.0)
Sales and service	8 (3.7)	3 (2.6)	5 (5.0)
Others	30 (14.0)	17 (14.9)	13 (12.9)
None	28 (13.0)	14 (12.3)	14 (13.9)
Family history of rheumatic disease	26 (12.1)	12 (10.5)	14 (13.9)
RA	18	12	6
SLE	8	1	7
Sjogren's disease	2	0	2
Comorbidity			
Hypertension	54 (25.1)	30 (26.3)	24 (23.8)
Diabetes mellitus	17 (7.9)	8 (7.0)	9 (8.9)
Dyslipidemia	37 (17.2)	21 (18.4)	16 (15.8)
Heart failure	3 (1.4)	1 (0.9)	2 (2.0)
Myocardial infarction	2 (0.9)	2 (1.8)	0 (0.0)
Coronary artery disease	6 (2.8)	1 (0.9)	5 (5.0)
Chronic renal failure	0 (0.0)	0 (0.0)	0 (0.0)
Conventional DMARDs			
Methotrexate	99 (46.0)	97 (85.1)	2 (2.0)
Hydroxychloroquine	177 (82.3)	79 (69.3)	98 (97.0)
Sulfasalazine	33 (15.3)	32 (28.1)	1 (1.0)
Leflunomide	6 (2.8)	5 (4.4)	1 (1.0)
Tacrolimus	10 (4.7)	6 (5.3)	4 (4.0)
Azathioprine	9 (4.2)	0 (0.0)	9 (8.9)
Mycophenolate mofetil	13 (6.0)	0 (0.0)	13 (12.9)

Supplementary Table 1. Continued

	Total (n = 215)	RA (n = 114)	SLE (n = 101)
Biologics/targeted synthetic DMARDs			
TNF inhibitors	12 (5.6)	12 (10.5)	0 (0.0)
IL-6R inhibitors	1 (0.5)	1 (0.9)	0 (0.0)
Janus kinase inhibitors	6 (2.8)	6 (2.1)	0 (0.0)

Values are presented as mean $\pm$ standard deviation, number (%), or number only.

RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; DMARDs, disease-modifying antirheumatic drugs; TNF, tumor necrosis factor; IL-6R, interleukin-6 receptor.